Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 4/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953073 | 1.00 | MPO (0.41) | MPOIDO1AGXTLOXL2TAAR1 | |
| Hydrochloric Acid SCHEMBL29951319 | 0.98 | MPO (0.40) | MPOIDO1AGXTLOXL2TAAR1 | |
| Hydrochloric Acid SCHEMBL3761659 | 0.98 | MPO (0.40) | MPOIDO1AGXTLOXL2TAAR1 | |
| SCHEMBL9938058 | 0.84 | MPO (0.41) | MPOIDO1AGXTLOXL2TAAR1 | |
| Hydrochloric Acid SCHEMBL3769431 | 0.82 | MPO (0.40) | MPOIDO1AGXTLOXL2TAAR1 | |
| SCHEMBL902030 | 0.82 | IDO1 (0.34) | IDO1AGXTKDM4ESMN1; SMN2LIPE | |
| SCHEMBL16576644 | 0.77 | RIPK1 (0.35) | IDO1AGXTKDM4ESMN1; SMN2LIPE | |
| SCHEMBL28983761 | 0.77 | IDO1 (0.39) | IDO1AGXTSMN1; SMN2LIPE | |
| SCHEMBL30396772 | 0.77 | IDO1 (0.39) | IDO1AGXTSMN1; SMN2LIPE | |
| SCHEMBL12215820 | 0.74 | CA3 (0.52) | MPOIDO1AGXTLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041442-A1 | DIAMINO LIPID (DAL) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING AN IMMUNOTHERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION | 2025-02-06 | — | — | US | disclosed |
| EP-4444280-A1 | DIAMINO LIPID (DAL) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING AN IMMUNOTHERAPEUTIC AGENT | Ohio State Innovation Foundation (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107400-A1 | DIAMINO LIPID (DAL) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING AN IMMUNOTHERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11021435-B2 | Serotonin receptor-targeting compounds and methods | NORTHEASTERN UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| US-10690675-B2 | Methods for enriching glycopeptides for global analysis of glycoproteins | GEORGIA TECH RESEARCH CORPORATION (US) | 2020-06-23 | — | — | US | disclosed |
| US-10548856-B2 | Compounds and methods for modulating serotonin receptors in the periphery | NORTHEASTERN UNIVERSITY (US) | 2020-02-04 | — | — | US | disclosed |
| US-10088476-B2 | Volume response sensors having analyte controlled reversible crosslinking | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180125798-A1 | Compounds and Methods for Modulating Serotonin Receptors in the Periphery | NORTHEASTERN UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-20180125798-A1 | Compounds and Methods for Modulating Serotonin Receptors in the Periphery | NORTHEASTERN UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-20170081273-A1 | Serotonin Receptor-Targeting Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| US-20170081273-A1 | Serotonin Receptor-Targeting Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| US-20160252505-A1 | VOLUME RESPONSE SENSORS HAVING ANALYTE CONTROLLED REVERSIBLE CROSSLINKING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOI S (US) | 2016-09-01 | — | — | US | disclosed |
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125798-A1 | Compounds and Methods for Modulating Serotonin Receptors in the Periphery | HTR5A, HTR3A, HTR1A | MPO 3433/4885IDO1 276/4885AGXT 2485/4885 |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | MPO 2336/4885IDO1 2449/4885AGXT 3429/4885 |
| US-20250041442-A1 | DIAMINO LIPID (DAL) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING AN IMMUNOTHERAPEUTIC AGENT | IL17A, IL2, IL15 | MPO 223/4885IDO1 511/4885AGXT 1799/4885 |
| US-10548856-B2 | Compounds and methods for modulating serotonin receptors in the periphery | HTR5A, HTR3A, HTR1A | MPO 3433/4885IDO1 276/4885AGXT 2485/4885 |
| US-11021435-B2 | Serotonin receptor-targeting compounds and methods | HTR1A, HTR2C, HTR7 | MPO 4781/4885IDO1 202/4885AGXT 2908/4885 |
| US-10690675-B2 | Methods for enriching glycopeptides for global analysis of glycoproteins | SIGLEC7, SIGLEC9, FUT6 | MPO 2491/4885IDO1 4091/4885AGXT 1491/4885 |
| US-20170081273-A1 | Serotonin Receptor-Targeting Compounds and Methods | HTR1A, HTR2C, HTR7 | MPO 4781/4885IDO1 202/4885AGXT 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.